Ginkgo Bioworks Holdings, Inc.

DNA · NYSE · SIC 2836: Biological Products, (No Diagnostic Substances)
51
SEC Filings

Business Summary

PART I . Unless the context otherwise requires, all references in this section to the Company, Ginkgo, we, us, or our refer to the business of Ginkgo Bioworks Holdings, Inc. and our subsidiaries. Overview: Our Mission is to Make Biology Easier to Engineer Our mission is to make biology easier to engineer. That has never changed. Every choice weve made with respect to our business model, our platform, our people, and our culture is grounded in whether it will advance our mission. Why? Because: 1....

Next Earnings

Q2 FY2026 — expected 2026-09-12

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionDNAdiscussed_in_filing Artificial Intelligence
topic_mentionDNAdiscussed_in_filing Cybersecurity
topic_mentionDNAdiscussed_in_filing Trusted Computing
topic_mentionDNAdiscussed_in_filing Blockchain & Crypto
topic_mentionDNAdiscussed_in_filing Regulation
topic_mentionDNAdiscussed_in_filing Automotive
topic_mentionDNAdiscussed_in_filing Healthcare & Bio
topic_mentionDNAdiscussed_in_filing Sovereign & Government
topic_mentionDNAdiscussed_in_filing Artificial Intelligence
topic_mentionDNAdiscussed_in_filing Cybersecurity
topic_mentionDNAdiscussed_in_filing Trusted Computing
topic_mentionDNAdiscussed_in_filing Blockchain & Crypto
topic_mentionDNAdiscussed_in_filing Regulation
topic_mentionDNAdiscussed_in_filing Automotive
topic_mentionDNAdiscussed_in_filing Healthcare & Bio
topic_mentionDNAdiscussed_in_filing Sovereign & Government
topic_mentionDNAdiscussed_in_filing Artificial Intelligence
topic_mentionDNAdiscussed_in_filing Cybersecurity
topic_mentionDNAdiscussed_in_filing Trusted Computing
topic_mentionDNAdiscussed_in_filing Blockchain & Crypto

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-262025-12-310001628280-26-012346EDGAR92K words
2025-02-252024-12-310001628280-25-007819EDGAR—
2024-02-292023-12-310001628280-24-008052EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001628280-25-050193EDGAR25K words
2025-08-072025-06-300001628280-25-038982EDGAR—
2025-05-062025-03-310001628280-25-022761EDGAR—
2024-11-122024-09-300001628280-24-047284EDGAR—
2024-08-082024-06-300001628280-24-036231EDGAR—
2024-05-092024-03-310001628280-24-022229EDGAR—
2023-11-082023-09-300001628280-23-037927EDGAR—
2023-08-092023-06-300000950170-23-040721EDGAR—
2023-05-102023-03-310000950170-23-020535EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-02-270001628280-26-012552EDGAR40K words
2026-02-260001628280-26-012339EDGAR—
2025-12-230001628280-25-058791EDGAR—
2025-11-060001830214-25-000013EDGAR—
2025-09-040001830214-25-000009EDGAR—
2025-08-290001628280-25-041399EDGAR—
2025-08-070001628280-25-038981EDGAR—
2025-06-130001628280-25-031304EDGAR—
2025-05-210001628280-25-027058EDGAR—
2025-05-060001628280-25-022759EDGAR—

51 total filings indexed. 29 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001830214
TickerDNA
ExchangeNYSE
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 1297d9c9ce411a66d54c6f7a185b7369e4bed577bd08265d4cf5d7e4e8ab4c9a
parent: 333d313742b0ce0eb8de411eb578f54dcf597e498dcba90efe91585d9a9cfbd0
content hash: 0ba910eed6a78353b48a980975b4f3a8ba008a3a1b1db1b0c9de485c804b2d37
signed: 2026-04-13T04:44:41.193Z
sources: 12 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf